Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Cue Biopharma, Inc. before investing.

In this article, we go over a few key elements for understanding Cue Biopharma, Inc.’s stock price such as:

• Cue Biopharma, Inc.’s current stock price and volume
• Why Cue Biopharma, Inc.’s stock price changed recently
• Upgrades and downgrades for CUE from analysts
• CUE’s stock price momentum as measured by its relative strength

About Cue Biopharma, Inc. (CUE)

Before we jump into Cue Biopharma, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Cue Biopharma, Inc., a clinical-stage therapeutics company, focuses on developing various therapies for immunological disorders. The company’s lead asset is CUE-221, an anti-IgE antibody with a dual-mechanism of action currently in Phase 2 development for allergic diseases. It also developed the Immuno-STAT platform, which targets disease-specific T cells in vivo without broad immune modulation. The company’s lead autoimmune candidate is CUE-401, a bifunctional IL-2 and TGF-B program that is advancing towards Phase 1 development to regulate inflammation and drive Treg-mediated tolerance. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.

Want to learn more about Cue Biopharma, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Cue Biopharma, Inc..

Cue Biopharma, Inc.’s Stock Price as of Market Close

As of July 24, 2026, 4:00 PM, CST, Cue Biopharma, Inc.’s stock price was $32.120.

Cue Biopharma, Inc. is down 2.93% from its previous closing price of $33.090.

During the last market session, Cue Biopharma, Inc.’s stock traded between $31.150 and $33.520. Currently, there are approximately 4.81 million shares outstanding for Cue Biopharma, Inc..

Cue Biopharma, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Cue Biopharma, Inc. Stock Price History

Cue Biopharma, Inc.’s (CUE) price is currently up 1.77% so far this month.

During the month of July, Cue Biopharma, Inc.’s stock price has reached a high of $45.500 and a low of $25.700.

Over the last year, Cue Biopharma, Inc. has hit prices as high as $45.500 and as low as $4.971. Year to date, Cue Biopharma, Inc.’s stock is up 250.58%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Cue Biopharma, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of July 24, 2026, there were 0 analysts who downgraded Cue Biopharma, Inc.’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate Cue Biopharma, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Cue Biopharma, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Cue Biopharma, Inc.’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Cue Biopharma, Inc. (CUE) by visiting AAII Stock Evaluator.

Relative Price Strength of Cue Biopharma, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of July 24, 2026, Cue Biopharma, Inc. has a weighted four-quarter relative price strength of 25.81%, which translates to a Momentum Score of 95 and is considered to be Very Strong.

Want to learn more about how Cue Biopharma, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Cue Biopharma, Inc. Stock Price: Bottom Line

As of July 24, 2026, Cue Biopharma, Inc.’s stock price is $32.120, which is down 2.93% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Cue Biopharma, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.